Description
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company.
The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an ideal source for creating cell therapy product candidates.
The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573.